bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 1 from Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients
Authors: Sabbatini Paul , Tsuji Takemasa , Ferran Luis , Ritter Erika , Sedrak Christine , Tuballes Kevin , Jungbluth Achim A. , Ritter Gerd , Aghajanian Carol , Bell-McGuinn Katherine , Hensley Martee L. , Konner Jason , Tew William , Spriggs David R. , Hoffman Eric W. , Venhaus Ralph , Pan Linda , Salazar Andres M. , Diefenbach Catherine Magid , Old Lloyd J. , Gnjatic Sacha
Published: April 2023

PDF file - 2015K, Injection site reaction in patient M21
Supplemental Table 1 from A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis
Authors: Reiss Kim A. , Herman Joseph M. , Zahurak Marianna , Brade Anthony , Dawson Laura A. , Scardina Angela , Joffe Caitlin , Petito Emily , Hacker-Prietz Amy , Kinders Robert J. , Wang Lihua , Chen Alice , Temkin Sarah , Horiba Naomi , Siu Lillian L. , Azad Nilofer S.
Published: April 2023

Treatment regimens, platinum-sensitivity and BRCA status of ovarian and fallopian tube cancer patients.
Supplementary Table S1 from High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab
Authors: Scaltriti Maurizio , Nuciforo Paolo , Bradbury Ian , Sperinde Jeff , Agbor-Tarh Dominique , Campbell Christine , Chenna Ahmed , Winslow John , Serra Violeta , Parra Josep Lluis , Prudkin Ludmila , Jimenez José , Aura Claudia , Harbeck Nadia , Pusztai Lajos , Ellis Catherine , Eidtmann Holger , Arribas Joaquin , Cortes Javier , de Azambuja Evandro , Piccart Martine , Baselga José
Published: April 2023

Supplementary Table S1. Multivariate Models in the IHC 3+ Subgroup
Supplementary Table 1 from Ectopic Expression of Cancer–Testis Antigens in Cutaneous T-cell Lymphoma Patients
Authors: Litvinov Ivan V. , Cordeiro Brendan , Huang Yuanshen , Zargham Hanieh , Pehr Kevin , Doré Marc-André , Gilbert Martin , Zhou Youwen , Kupper Thomas S. , Sasseville Denis
Published: April 2023

PDF file - 209KB, Primers used for RT-PCR experiments.
Supplementary Figure 3 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
Authors: Filipazzi Paola , Pilla Lorenzo , Mariani Luigi , Patuzzo Roberto , Castelli Chiara , Camisaschi Chiara , Maurichi Andrea , Cova Agata , Rigamonti Gianluigi , Giardino Felicetta , Di Florio Annabella , Asioli Marco , Frati Paola , Sovena Gloria , Squarcina Paola , Maio Michele , Danielli Riccardo , Chiarion-Sileni Vanna , Villa Antonello , Lombardo Claudia , Tragni Gabrina , Santinami Mario , Parmiani Giorgio , Rivoltini Licia
Published: April 2023

PDF file - 64K, Analysis of chemokine receptor expression
Supplementary Tables S1-5 from Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non–Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR
Authors: Watanabe Masaru , Kawaguchi Tomoya , Isa Shun-ichi , Ando Masahiko , Tamiya Akihiro , Kubo Akihito , Saka Hideo , Takeo Sadanori , Adachi Hirofumi , Tagawa Tsutomu , Kakegawa Seiichi , Yamashita Motohiro , Kataoka Kazuhiko , Ichinose Yukito , Takeuchi Yukiyasu , Sakamoto Kazuhiro , Matsumura Akihide , Koh Yasuhiro
Published: April 2023

Supplementary Tables S1-5. Table S1: Primers and probes used for droplet digital PCR (ddPCR). Table S2: Determination of the limit of blank (LOB) from wild-type control DNA, normal human genomic DNA, and EGFR wild-type A549 genomic DNA. Table S3: Determination of the limit of blank (LOB) using genomic DNA from adjacent normal tissue samples of EGFR-activating mutation positive adenocarcinoma and EGFR wild-type squamous cell carcinoma. Table S4: Concordance between ddPCR and deep sequencing of EGFR T790M mutation. Table S5: Distribution of amplifiable DNA concentrations in the 377 analyzed samples.
Supplementary Figures S1-8 from Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non–Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR
Authors: Watanabe Masaru , Kawaguchi Tomoya , Isa Shun-ichi , Ando Masahiko , Tamiya Akihiro , Kubo Akihito , Saka Hideo , Takeo Sadanori , Adachi Hirofumi , Tagawa Tsutomu , Kakegawa Seiichi , Yamashita Motohiro , Kataoka Kazuhiko , Ichinose Yukito , Takeuchi Yukiyasu , Sakamoto Kazuhiro , Matsumura Akihide , Koh Yasuhiro
Published: April 2023

Supplementary Figures S1-8. Figure S1: Flowchart for mutation call. Figure S2: Quantification of performance of ddPCR analysis for EGFR T790M mutation. Figure S3: Analytical sensitivity of 0.001% for the ddPCR assay. Figure S4: Determination of false-positive events from wild-type control DNA and normal human genomic DNA. Figure S5: Determination of false-positive events in genomic DNA from formalin-fixed paraffin-embedded (FFPE) A549 cells. Figure S6: Detection of EGFR T790M mutant alleles in patients with EGFR T790M-containing primary tumors. Figure S7: Comparison of T790M mutation detection in 6 samples by different operators. Figure S8: Reproducibility of ddPCR analysis from 16 T790M-positive samples.
Supplementary Table 1 from Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide
Authors: O'Donnell Peter H. , Karovic Sanja , Karrison Theodore G. , Janisch Linda , Levine Matthew R. , Harris Pamela J. , Polite Blase N. , Cohen Ezra E.W. , Fleming Gini F. , Ratain Mark J. , Maitland Michael L.
Published: April 2023

Adverse Events.
Supplementary figure 1 from Bevacizumab Preconditioning Followed by Etoposide and Cisplatin Is Highly Effective in Treating Brain Metastases of Breast Cancer Progressing from Whole-Brain Radiotherapy
Authors: Lu Yen-Shen , Chen Tom Wei-Wu , Lin Ching-Hung , Yeh Dah-Cherng , Tseng Ling-Ming , Wu Pei-Fang , Rau Kun-Ming , Chen Bang-Bin , Chao Ta-Chung , Huang Shu-Min , Huang Chiun-Sheng , Shih Tiffany Ting-Fang , Cheng Ann-Lii
Published: April 2023

Supplementary figure 1. Kaplan-Meier survival curves of patients who completed 6 cycles of BEEP regimen, categorized by whether received further bevacizumab-based maintenance treatment.
Data Supplement from Reversible LSD1 Inhibition Interferes with Global EWS/ETS Transcriptional Activity and Impedes Ewing Sarcoma Tumor Growth
Authors: Sankar Savita , Theisen Emily R. , Bearss Jared , Mulvihill Timothy , Hoffman Laura M. , Sorna Venkataswamy , Beckerle Mary C. , Sharma Sunil , Lessnick Stephen L.
Published: April 2023

Supplementary materials, including supplementary Methods, Table S3. Primer Sequences. Figure S1. Transcriptional Profiling of HCI2509 in A673 and TTC-466. Figure S2. Morphological Changes in TTC-466 with HCI2509 Treatment. Figure S3. Effects of HCI2509 on Transformation, Methylation, and Apoptosis. Figure S4. Regulation of HMOX1. Figure S5. Tumor Volume, Body Weight, and Blood Counts.
Data Supplement from Reversible LSD1 Inhibition Interferes with Global EWS/ETS Transcriptional Activity and Impedes Ewing Sarcoma Tumor Growth
Authors: Sankar Savita , Theisen Emily R. , Bearss Jared , Mulvihill Timothy , Hoffman Laura M. , Sorna Venkataswamy , Beckerle Mary C. , Sharma Sunil , Lessnick Stephen L.
Published: April 2023

Supplementary Table S2. Nine-Gene Panel qRT-PCR Validation p-values.
Related Article from Are Short Telomeres Hallmarks of Cancer Recurrence?
Authors: Shay Jerry W.
Published: April 2023

Related Article from Are Short Telomeres Hallmarks of Cancer Recurrence?
Video 1 from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
Authors: Bacac Marina , Fauti Tanja , Sam Johannes , Colombetti Sara , Weinzierl Tina , Ouaret Djamila , Bodmer Walter , Lehmann Steffi , Hofer Thomas , Hosse Ralf J. , Moessner Ekkehard , Ast Oliver , Bruenker Peter , Grau-Richards Sandra , Schaller Teilo , Seidl Annette , Gerdes Christian , Perro Mario , Nicolini Valeria , Steinhoff Nathalie , Dudal Sherri , Neumann Sebastian , von Hirschheydt Thomas , Jaeger Christiane , Saro Jose , Karanikas Vaios , Klein Christian , Umaña Pablo
Published: April 2023

Representative videos of intravital two-photon (2P) microscopy of tumors treated with untargeted TCB. Tumor cells red, T cells green.
Supplementary Table S2 from FBW7 (F-box and WD Repeat Domain-Containing 7) Negatively Regulates Glucose Metabolism by Targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) Axis in Pancreatic Cancer
Authors: Ji Shunrong , Qin Yi , Liang Chen , Huang Run , Shi Si , Liu Jiang , Jin Kaizhou , Liang Dingkong , Xu Wenyan , Zhang Bo , Liu Liang , Liu Chen , Xu Jin , Ni Quanxing , Chiao Paul J. , Li Min , Yu Xianjun
Published: April 2023

Primers used in the text.
Supplementary Figure 6 from Neuroblastoma Killing Properties of Vδ2 and Vδ2-Negative γδT Cells Following Expansion by Artificial Antigen-Presenting Cells
Authors: Fisher Jonathan P.H. , Yan Mengyong , Heuijerjans Jennifer , Carter Lisa , Abolhassani Ayda , Frosch Jennifer , Wallace Rebecca , Flutter Barry , Capsomidis Anna , Hubank Mike , Klein Nigel , Callard Robin , Gustafsson Kenth , Anderson John
Published: April 2023

PDF file - 251K, Supplementary figure 6. NKG2D expression of expanded gammadeltaT cell subsets.
Supplementary tables from Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses
Authors: Sundaresan Tilak K. , Sequist Lecia V. , Heymach John V. , Riely Gregory J. , Jänne Pasi A. , Koch Walter H. , Sullivan James P. , Fox Douglas B. , Maher Robert , Muzikansky Alona , Webb Andrew , Tran Hai T. , Giri Uma , Fleisher Martin , Yu Helena A. , Wei Wen , Johnson Bruce E. , Barber Thomas A. , Walsh John R. , Engelman Jeffrey A. , Stott Shannon L. , Kapur Ravi , Maheswaran Shyamala , Toner Mehmet , Haber Daniel A.
Published: April 2023

Supplementary tables S1-S3. Supplementary Table S1: Institutional Tumor Genotyping Strategies. Supplementary Table S2: T790M Genotype by Modality. Supplementary Table S3: EGFR Primary Mutation Detection.
Supplementary Table S1 from Notch1 Signaling Regulates the Aggressiveness of Differentiated Thyroid Cancer and Inhibits SERPINE1 Expression
Authors: Yu Xiao-Min , Jaskula-Sztul Renata , Georgen Maria R. , Aburjania Zviadi , Somnay Yash R. , Leverson Glen , Sippel Rebecca S. , Lloyd Ricardo V. , Johnson Brian P. , Chen Herbert
Published: April 2023

Sequences of each primer for real-time quantitative PCR
Material and Methods (supplementary) from Notch1 Signaling Regulates the Aggressiveness of Differentiated Thyroid Cancer and Inhibits SERPINE1 Expression
Authors: Yu Xiao-Min , Jaskula-Sztul Renata , Georgen Maria R. , Aburjania Zviadi , Somnay Yash R. , Leverson Glen , Sippel Rebecca S. , Lloyd Ricardo V. , Johnson Brian P. , Chen Herbert
Published: April 2023

Described details of Western blot, clonogenic assay, cell migration assay, ex-vivo imaging, IHC and etc.
Supplementary Figure 2S from A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis
Authors: Hawkins Robert E. , Gore Martin , Shparyk Yaroslav , Bondar Vladimir , Gladkov Oleg , Ganev Tosho , Harza Mihai , Polenkov Serhii , Bondarenko Igor , Karlov Petr , Karyakin Oleg , Khasanov Rustem , Hedlund Gunnar , Forsberg Goran , Nordle Örjan , Eisen Timothy
Published: April 2023

Anti-SEA/E-120 vs exposure of Nap. Concentration of Nap after Nap at day 1 of treatment. Moving median of 8 overlapping subgroups of patients with different baseline anti-SEA/E-120 (pmol/mL). Median{plus minus}SE is depicted.
Supplemental Figure legends from The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic Leukemia
Authors: Matas-Céspedes Alba , Vidal-Crespo Anna , Rodriguez Vanina , Villamor Neus , Delgado Julio , Giné Eva , Roca-Ho Heleia , Menéndez Pablo , Campo Elías , López-Guillermo Armando , Colomer Dolors , Roué Gaël , Wiestner Adrian , Parren Paul W.H.I. , Doshi Parul , van Bueren Jeroen Lammerts , Pérez-Galán Patricia
Published: April 2023

Legends of Figures S1-S5
Suppl. Fig. 2 from Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non–Small Cell Lung Cancer
Authors: Sharma Ashish , Bender Sabine , Zimmermann Martina , Riesterer Oliver , Broggini-Tenzer Angela , Pruschy Martin N.
Published: April 2023

IR-induced cleavage of the proform of ADAM17 to active ADAM17 requires reactive oxygen species (ROS).
Supplementary Figure Legends from Development and Validation of a Novel Radiosensitivity Signature in Human Breast Cancer
Authors: Speers Corey , Zhao Shuang , Liu Meilan , Bartelink Harry , Pierce Lori J. , Feng Felix Y.
Published: April 2023

Supplementary Figure Legends from Development and Validation of a Novel Radiosensitivity Signature in Human Breast Cancer
Supplementary Figure 2 from Development and Validation of a Novel Radiosensitivity Signature in Human Breast Cancer
Authors: Speers Corey , Zhao Shuang , Liu Meilan , Bartelink Harry , Pierce Lori J. , Feng Felix Y.
Published: April 2023

Unsupervised hierarchical clustering using the gene expression of the 147 differentially expressed genes accurately clusters the radiation resistant cell lines (SF2 Gy >45%) from the radiation sensitive cell lines (SF 2 Gy <45%).
Supplementary table 6 from Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression
Authors: Lopez Sandra M. , Agoulnik Alexander I. , Zhang Manqi , Peterson Leif E. , Suarez Egla , Gandarillas Gregory A. , Frolov Anna , Li Rile , Rajapakshe Kimal , Coarfa Christian , Ittmann Michael M. , Weigel Nancy L. , Agoulnik Irina U.
Published: April 2023

NCOR1 signature
Supplemental Tables 1-5, Figures 1-2 from Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program
Authors: Smith Malcolm A. , Reynolds C. Patrick , Kang Min H. , Kolb E. Anders , Gorlick Richard , Carol Hernan , Lock Richard B. , Keir Stephen T. , Maris John M. , Billups Catherine A. , Lyalin Dmitry , Kurmasheva Raushan T. , Houghton Peter J.
Published: April 2023

Supplemental Tables 1-5, Figures 1-2. Supplemental Table I: Topotecan in vitro activity in the presence and absence of talazoparib (10 nM) Supplemental Table II. Efficacy of PPTP Single agents and combinations in Xenograft Models Supplemental Table III. Efficacy of Combination B against PPTP Xenograft Models Supplemental Table IV: Therapeutic Enhancement in vivo. Supplemental Table V. Responses to Tumor Models to Combination B (talazoparib plus low-dose temozolomide) Supplemental Figure 1. Kaplan-Meier estimates for Event-Free Survival in Ewing sarcoma xenograft models. Supplemental Figure 2. Quantification of total (cleaved + uncleaved) PARP, and cleaved PARP following 5 days treatment of TC-71R tumors with talazoparib, temozolomide or the combination. Relative levels of total and cleaved PARP are shown for parental TC-71 xenografts.
Supplementary Figure 3 from Dual HER2 Targeting Impedes Growth of HER2 Gene–Amplified Uterine Serous Carcinoma Xenografts
Authors: Groeneweg Jolijn W. , Hernandez Silvia F. , Byron Virginia F. , DiGloria Celeste M. , Lopez Hector , Scialabba Vanessa , Kim Minji , Zhang Ling , Borger Darrell R. , Tambouret Rosemary , Foster Rosemary , Rueda Bo R. , Growdon Whitfield B.
Published: April 2023

Supplementary Figure 3. Mouse weight changes over the course of each four-arm treatment study. In all experiments, lapatinib and trastuzumab treatments did not significantly affect mouse weights. Mice were weighed weekly, and the percent changes in weight compared to baseline weights (100%) are shown. Error bars represent the standard error of the mean.
Supplementary Figure Legends from Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy
Authors: Gradishar William J. , Yardley Denise A. , Layman Rachel , Sparano Joseph A. , Chuang Ellen , Northfelt Donald W. , Schwartz Gary N. , Youssoufian Hagop , Tang Shande , Novosiadly Ruslan , Forest Amelie , Nguyen Tuan S. , Cosaert Jan , Grebennik Dmitri , Haluska Paul
Published: April 2023

Supplementary Figure Legends for Figures S1 and S2
Supplememtary data. Appendix 2. Assay validation from The Prognostic and Predictive Value of Soluble Type IV Collagen in Colorectal Cancer: A Retrospective Multicenter Study
Authors: Rolff Hans Christian , Christensen Ib Jarle , Vainer Ben , Svendsen Lars Bo , Eefsen Rikke Løvendahl , Wilhelmsen Michael , Lund Ida Katrine , Høyer-Hansen Gunilla , Nielsen Hans Jørgen , Illemann Martin
Published: April 2023

This text file describes how the assay was validated
Supplementary Figures 1-3 from ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer
Authors: Manna Subrata , Bostner Josefine , Sun Yang , Miller Lance D. , Alayev Anya , Schwartz Naomi S. , Lager Elin , Fornander Tommy , Nordenskjöld Bo , Yu Jane J. , Stål Olle , Holz Marina K.
Published: April 2023

Supplementary figure 1: Validation of the ERRα antibody used for immunohistochemical analysis; Supplementary Figure 2: The prognostic value of ERRα protein expression and subcellular location in adjuvant-untreated ER-negative patients; Supplementary Figure 3: ERRα protein expression is not prognostic in ER-positive breast cancer.
Supplementary Figure Legends and Materials and Methods from siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate Cancer
Authors: Yamamoto Yoshiaki , Lin Paulo J.C. , Beraldi Eliana , Zhang Fan , Kawai Yoshihisa , Leong Jeffrey , Katsumi Hidemasa , Fazli Ladan , Fraser Robert , Cullis Pieter R. , Gleave Martin
Published: April 2023

Supplementary Figure Legends S1-4. Supplementary Materials and Methods: Antibodies used for western blotting.
Supplementary Tables 1 and 2 from PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma
Authors: Zamagni Elena , Nanni Cristina , Mancuso Katia , Tacchetti Paola , Pezzi Annalisa , Pantani Lucia , Zannetti Beatrice , Rambaldi Ilaria , Brioli Annamaria , Rocchi Serena , Terragna Carolina , Martello Marina , Marzocchi Giulia , Borsi Enrica , Rizzello Ilaria , Fanti Stefano , Cavo Michele
Published: April 2023

Supplementary Tables 1 and 2. Supplementary Table 1 describes Summary of FDG PET/CT positivity criteria Supplementary Table 2 contains Univariate analysis of baseline and post-treatment variables adversely affecting progression-free survival and overall survival
Supplemental Figures 1-6 from Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models
Authors: Benito Juliana , Ramirez Marc S. , Millward Niki Zacharias , Velez Juliana , Harutyunyan Karine G. , Lu Hongbo , Shi Yue-xi , Matre Polina , Jacamo Rodrigo , Ma Helen , Konoplev Sergej , McQueen Teresa , Volgin Andrei , Protopopova Marina , Mu Hong , Lee Jaehyuk , Bhattacharya Pratip K. , Marszalek Joseph R. , Davis R. Eric , Bankson James A. , Cortes Jorge E. , Hart Charles P. , Andreeff Michael , Konopleva Marina
Published: April 2023

Supplementary Figure S1. TH-302 has potent antitumor activity in a 3D in vitro co-culture system of leukemia cells and bone marrow-derived mesenchymal stromal cells that recapitulates the multidimensional BM niche Supplementary Figure S2. Hypoxia is present in spheroids as indicated by PIMO positive staining in spheroids incubated with PIMO for 3hr before harvesting Supplementary figure S3. In vitro synergistic activity of TH-302 in combination with chemotherapy and demethylating agents Supplementary Figure S4. TH-302 has anti-leukemia activity in an in vivo primary AML xenograft murine model. Supplementary figure S5. In vitro synergistic activity of TH-302 in combination with sorafenib Supplementary figure S6 A, B. Assessment of BM hypoxia in AML/ETO bearing mice treated with TH-302 or chemotherapy
Supplementary Figure S5 from The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects
Authors: Shahbazi Jeyran , Liu Pei Y. , Atmadibrata Bernard , Bradner James E. , Marshall Glenn M. , Lock Richard B. , Liu Tao
Published: April 2023

JQ1 and panobinostat do not cooperatively regulate GSK3β and Aurora A expression, and LIN28B does not regulate Aurora A expression.
Supplementary Figure S2 from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
Authors: Jilaveanu Lucia B. , Parisi Fabio , Barr Meaghan L. , Zito Christopher R. , Cruz-Munoz William , Kerbel Robert S. , Rimm David L. , Bosenberg Marcus W. , Halaban Ruth , Kluger Yuval , Kluger Harriet M.
Published: April 2023

A375Br cells were transfected with one of four siRNA clones directed against PLEKHA5 or a nontargeting control siRNA. Knock-down is demonstrated by Western blot.
Supplementary Figure 4 from Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients
Authors: Kurose Koji , Ohue Yoshihiro , Wada Hisashi , Iida Shinsuke , Ishida Takashi , Kojima Takashi , Doi Toshihiko , Suzuki Susumu , Isobe Midori , Funakoshi Takeru , Kakimi Kazuhiro , Nishikawa Hiroyoshi , Udono Heiichiro , Oka Mikio , Ueda Ryuzo , Nakayama Eiichi
Published: April 2023

Antibody response and CD4 and CD8 T-cell responses during treatment.
Supplementary Figure 2 from Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients
Authors: Kurose Koji , Ohue Yoshihiro , Wada Hisashi , Iida Shinsuke , Ishida Takashi , Kojima Takashi , Doi Toshihiko , Suzuki Susumu , Isobe Midori , Funakoshi Takeru , Kakimi Kazuhiro , Nishikawa Hiroyoshi , Udono Heiichiro , Oka Mikio , Ueda Ryuzo , Nakayama Eiichi
Published: April 2023

Clinical course of 3 NSCLC patients evaluated as SD at 12 weeks after treatment.
Supplementary Figures 1-2, Supplementary Table 1 from Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma
Authors: Jain Salvia , Jirau-Serrano Xavier , Zullo Kelly M. , Scotto Luigi , Palermo Carmine F. , Sastra Stephen A. , Olive Kenneth P. , Cremers Serge , Thomas Tiffany , Wei Ying , Zhang Yuan , Bhagat Govind , Amengual Jennifer E. , Deng Changchun , Karan Charles , Realubit Ronald , Bates Susan E. , O'Connor Owen A.
Published: April 2023

Supplementary Figures 1-2, Supplementary Table 1. Supplementary Figure 1: Highthroughput Matrix For H9 and HH. Highthroughput screen was used to determine the synergistic interaction in vitro in H9 and HH T-cell lines. (A) Depicts the observed percent of inhibition matrix following 48 hours of treatment with romidepsin and pralatrexate. Romidepsin concentration is labelled on the y-axis in μM while the pralatrexate concentration if labelled on the x-axis in μM. (B) Depicts the observed percent of inhibition matrix following 72 hours of treatment with romidepsin and pralatrexate. Supplementary Figure 2. Generation of stable mCherryLuciferase expressing H9 and HuT-78 cell line by FACS sorting. Flow cytometric analysis for mCherry expression in H9 control cells (A), in stably transduced H9 cells transfected with the pGLCherryLuciferase plasmid and enriched by FACS (B), in HuT-78 control cells (C), in stably transduced HuT-78 cells transfected with the pGLCherryLuciferase plasmid and enriched by FACS (D). Supplementary Table 1: Forward and reverse primer sequences are listed for all genes evaluated by qPCR.
Supplementary Table 1 from Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte–Derived HLA-Ligandome Using a Reverse Immunology Approach
Authors: Hombrink Pleun , Hassan Chopie , Kester Michel G.D. , Jahn Lorenz , Pont Margot J. , de Ru Arnoud H. , van Bergen Cornelis A.M. , Griffioen Marieke , Falkenburg J.H. Frederik , van Veelen Peter A. , Heemskerk Mirjam H.M.
Published: April 2023

Supplementary Table 1. Eluted published MiHA epitopes
Supplemental Figure 3 from Hepatitis B Virus X Protein (HBx) Is Responsible for Resistance to Targeted Therapies in Hepatocellular Carcinoma: Ex Vivo Culture Evidence
Authors: Huang Pinbo , Zhuang Baoxiong , Zhang Heyun , Yan Haiyan , Xiao Zhiyu , Li Wenbin , Zhang Jianlong , Tang Qibin , Hu Kaishun , Koeffler H. Phillip , Wang Jie , Yin Dong
Published: April 2023

Supplemental Figure 3. HBx is associated with bortezomib resistance in HBV/HBx-related HCC cells.
Supplemental Figure 2 from Hepatitis B Virus X Protein (HBx) Is Responsible for Resistance to Targeted Therapies in Hepatocellular Carcinoma: Ex Vivo Culture Evidence
Authors: Huang Pinbo , Zhuang Baoxiong , Zhang Heyun , Yan Haiyan , Xiao Zhiyu , Li Wenbin , Zhang Jianlong , Tang Qibin , Hu Kaishun , Koeffler H. Phillip , Wang Jie , Yin Dong
Published: April 2023

Supplemental Figure 2. The relationship between bortezomib resistance and changes in the rate of proliferation.
Supplemental Figure 1 from Hepatitis B Virus X Protein (HBx) Is Responsible for Resistance to Targeted Therapies in Hepatocellular Carcinoma: Ex Vivo Culture Evidence
Authors: Huang Pinbo , Zhuang Baoxiong , Zhang Heyun , Yan Haiyan , Xiao Zhiyu , Li Wenbin , Zhang Jianlong , Tang Qibin , Hu Kaishun , Koeffler H. Phillip , Wang Jie , Yin Dong
Published: April 2023

Supplemental Figure 1. Ex vivo tumor tissue culture protocol and the viability of the ex vivo cultured tissues.
Supplementary Figure 4 from Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
Authors: Martens Alexander , Wistuba-Hamprecht Kilian , Foppen Marnix Geukes , Yuan Jianda , Postow Michael A. , Wong Phillip , Romano Emanuela , Khammari Amir , Dreno Brigitte , Capone Mariaelena , Ascierto Paolo A. , Di Giacomo Anna Maria , Maio Michele , Schilling Bastian , Sucker Antje , Schadendorf Dirk , Hassel Jessica C. , Eigentler Thomas K. , Martus Peter , Wolchok Jedd D. , Blank Christian , Pawelec Graham , Garbe Claus , Weide Benjamin
Published: April 2023

Correlations between adverse events and overall survival, clinical response, or biomarker categories. Overall survival was not different between patients stratified according to the occurrence of adverse events (AEs) in general (A) or immune-related AEs (irAEs). (B). Kaplan-Meier analysis is presented and censoring is indicated by vertical lines; p-values were calculated by log rank statistics (A&B). No correlations were observed between the occurrence of irAEs during ipilimumab treatment and the best tumor response (C, D) nor with the proposed combination groups of baseline biomarkers according to the combination model 1 (E) or combination model 2 (F). The best overall tumor response according to immune-related response criteria (irRC) was analyzed either as the rate of patients with an irRC response (sum of those with complete or partial responses) or irRC benefit (sum of those with complete responses, partial responses and stable disease). Differences were not statistically significant.
Supplementary Figure 2 from Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
Authors: Martens Alexander , Wistuba-Hamprecht Kilian , Foppen Marnix Geukes , Yuan Jianda , Postow Michael A. , Wong Phillip , Romano Emanuela , Khammari Amir , Dreno Brigitte , Capone Mariaelena , Ascierto Paolo A. , Di Giacomo Anna Maria , Maio Michele , Schilling Bastian , Sucker Antje , Schadendorf Dirk , Hassel Jessica C. , Eigentler Thomas K. , Martus Peter , Wolchok Jedd D. , Blank Christian , Pawelec Graham , Garbe Claus , Weide Benjamin
Published: April 2023

Discriminatory ability of combination models. The concordance index (c-index, y-axis) was calculated for the combination of factors with independent impact according to Cox regression analysis (model 6.1) and 13 alternative combination models considering 5, 7, or 8 factors (A). The numbers refer to the rows in A. The c-indices are presented according to the number of combined factors (B). The combination model with highest discriminatory ability (7.4), which considered regulatory T cells in addition to the 6 factors with independent impact according to Cox regression analysis was chosen as combination model 1. No further increase of the c-index compared to combination model 1 was observed if one of the 3 remaining factors was additionally considered (models 8.1, 8.2, 8.3). C-indices were calculated for different combination models accounting for the number of unfavorable values of all factors considered in the given model (C). All possible models derived from combinations of the five routine factors were considered. The c-indices are presented according to the number of considered factors (D). The model with highest discriminatory ability (4.1) was selected.
Data Supplement from CD44 Expression Denotes a Subpopulation of Gastric Cancer Cells in Which Hedgehog Signaling Promotes Chemotherapy Resistance
Authors: Yoon Changhwan , Park Do Joong , Schmidt Benjamin , Thomas Nicholas J. , Lee Hae-June , Kim Teresa S. , Janjigian Yelena Y. , Cohen Deirdre J. , Yoon Sam S.
Published: April 2023

Supplementary Figure 1 - Expression of CD44, other stem cell markers, and Hedgehog pathway proteins in gastric cancer cells.
Supplementary Figure S1 from Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384
Authors: Leiker Andrew J. , DeGraff William , Choudhuri Rajani , Sowers Anastasia L. , Thetford Angela , Cook John A. , Van Waes Carter , Mitchell James B.
Published: April 2023

Supplementary Figure S1. Survival of UMSCC1 cells as a function of treatment time with PF- 05212384 (10Î¼M) treatment alone, a function of time with PF-05212384 (10Î¼M) treatment followed by irradiation (8 Gy), or a function of time with DMSO control (10Î¼M) treatment followed by irradiation (8 Gy)
Supplementary Table S1 from Cotargeting of Epidermal Growth Factor Receptor and PI3K Overcomes PI3K–Akt Oncogenic Dependence in Pancreatic Ductal Adenocarcinoma
Authors: Wong Matthew H. , Xue Aiqun , Julovi Sohel M. , Pavlakis Nick , Samra Jaswinder S. , Hugh Thomas J. , Gill Anthony J. , Peters Lyndsay , Baxter Robert C. , Smith Ross C.
Published: April 2023

Table S1: IC50 values for inhibition of proliferation of (A) 5 PDAC cell lines and (B) 2 derived erlotinib-resistant (ER) cell lines, in response to inhibitors of EGFR (erlotinib, gefitinib), IGF1R (NVP-AEW541), MEK (PD-98059), PI3K (LY-294002), PI3Kï�¡ (NVP-BYL719) and PI3K/mTOR (NVP-BEZ235). Average ï‚± SEM of 6 experiments. Highly insensitive cell lines are shaded in grey in (A). Paired t-test statistics was calculated for resistance in (B).
Supplementary Figure 1 from Early Changes in Circulating Tumor Cells Are Associated with Response and Survival Following Treatment of Metastatic Neuroendocrine Neoplasms
Authors: Khan Mohid S. , Kirkwood Amy A. , Tsigani Theodora , Lowe Helen , Goldstein Robert , Hartley John A. , Caplin Martyn E. , Meyer Tim
Published: April 2023

Kaplan-Meier survival curves showing effect of baseline CTCs grouped in tertiles on OS (A); post-treatment CTCs on OS (B); baseline CgA on OS (C); and post-treatment CgA OS (D).
Supplemental Figure 3 from The Retinoblastoma Tumor Suppressor Modulates DNA Repair and Radioresponsiveness
Authors: Thangavel Chellappagounder , Boopathi Ettickan , Ciment Steve , Liu Yi , O' Neill Raymond , Sharma Ankur , McMahon Steve B. , Mellert Hestia , Addya Sankar , Ertel Adam , Birbe Ruth , Fortina Paolo , Dicker Adam P. , Knudsen Karen E. , Den Robert B.
Published: April 2023

Supplemental Figure 3. NFκB is retained in the cytoplasm in the presence of an IκB dominant negative.
Supp. Table 4 from Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma
Authors: Calles Antonio , Sholl Lynette M. , Rodig Scott J. , Pelton Ashley K. , Hornick Jason L. , Butaney Mohit , Lydon Christine , Dahlberg Suzanne E. , Oxnard Geoffrey R. , Jackman David M. , Jänne Pasi A.
Published: April 2023

Table S4. LKB1 patient characteristics in KRAS mutant patients (n=148)*
Supp. Table 3 from Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma
Authors: Calles Antonio , Sholl Lynette M. , Rodig Scott J. , Pelton Ashley K. , Hornick Jason L. , Butaney Mohit , Lydon Christine , Dahlberg Suzanne E. , Oxnard Geoffrey R. , Jackman David M. , Jänne Pasi A.
Published: April 2023

Supplementary Table S3. List of LKB1 mutant lung adenocarcinoma specimens by OncoMap tested for LKB1 IHC.
Supplementary figures 1-10 from Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer
Authors: Varkaris Andreas , Corn Paul G. , Parikh Nila U. , Efstathiou Eleni , Song Jian H. , Lee Yu-Chen , Aparicio Ana , Hoang Anh G. , Gaur Sanchaika , Thorpe Lynnelle , Maity Sankar N. , Bar Eli Menashe , Czerniak Bogdan A. , Shao Yiping , Alauddin Mian , Lin Sue-Hwa , Logothetis Christopher J. , Gallick Gary E.
Published: April 2023

Supplemental Figure 1 (fig. S1). Representative whole body NaF-18 PET scan images after 44 days of (A) vehicle-treated and (B) cabozantinib-treated animals. Supplemental Figure 2 (fig. S2). Effect of cabozantinib on PDX tumor growth, animal weight, and survival. Supplemental Figure 3 (fig. S3). Representative images of viable islets of tumor cells in (A) Patients; (B) MDA PCa-118b grown intrafemurally; and (C) MDA PCa- 118b grown subcutaneously. Supplemental Figure 4 (fig. S4). Time-dependent effect of cabozantinib on expression and phosphorylation of primary and MET downstream targets. Supplemental Figure 5 (fig. S5). Relative expression of c-met mRNA in NT and knockdown cells as determined by qRT-PCR. Supplemental Figure 6 (fig. S6). MET expression and activity in NT and knockdown tumors. Supplemental Figure 7 (fig. S7): Quantitation of CD31 staining on bone tumors. Supplemental Figure 8 (fig. S8). Effects of cabozantinib on bone remodeling markers in the phase-2 clinical trial and growth and differentiation of primary osteoblasts. Supplemental Figure S9 (fig S9). Effect of cabozantinib on bone turnover in the Phase 2 trial and PDX grown intrafemurally. Supplemental Figure 10 (fig. S10). Quantitation of phospho-histone H3 staining.
Supplementary figure S4 from EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer
Authors: Dunne Philip D. , Dasgupta Sonali , Blayney Jaine K. , McArt Darragh G. , Redmond Keara L. , Weir Jessica-Anne , Bradley Conor A. , Sasazuki Takehiko , Shirasawa Senji , Wang Tingting , Srivastava Supriya , Ong Chee Wee , Arthur Ken , Salto-Tellez Manuel , Wilson Richard H. , Johnston Patrick G. , Van Schaeybroeck Sandra
Published: April 2023

Clinical relevance of EphA2 expression in CRC tissues.
Supplementary figure S3 from EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer
Authors: Dunne Philip D. , Dasgupta Sonali , Blayney Jaine K. , McArt Darragh G. , Redmond Keara L. , Weir Jessica-Anne , Bradley Conor A. , Sasazuki Takehiko , Shirasawa Senji , Wang Tingting , Srivastava Supriya , Ong Chee Wee , Arthur Ken , Salto-Tellez Manuel , Wilson Richard H. , Johnston Patrick G. , Van Schaeybroeck Sandra
Published: April 2023

Role of EFNA1 in invasion and migration of colorectal cancer cells.
Supplementary Figure 4 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Authors: Hall Connor P. , Reynolds C. Patrick , Kang Min H.
Published: April 2023

Suppl Fig 4. Effect on PI3K pathway. (A) AKT1 knockdown effect on BEZ235, dexamethasone, and BEZ235 plus dexamethasone cytotoxicity.
Supplementary Figure 3 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Authors: Hall Connor P. , Reynolds C. Patrick , Kang Min H.
Published: April 2023

Suppl Fig 3. Analysis of PI3K/AKT/mTOR pathway activity in ALL cell lines.
Supplemental Figure S5 from Chemotherapy Resistance in Diffuse-Type Gastric Adenocarcinoma Is Mediated by RhoA Activation in Cancer Stem-Like Cells
Authors: Yoon Changhwan , Cho Soo-Jeong , Aksoy Bülent Arman , Park Do Joong , Schultz Nikolaus , Ryeom Sandra W. , Yoon Sam S.
Published: April 2023

Expression MYPT and effect of fasudil on spheroid formation, migration, and invasion.
Supplemental Figure S1 from Chemotherapy Resistance in Diffuse-Type Gastric Adenocarcinoma Is Mediated by RhoA Activation in Cancer Stem-Like Cells
Authors: Yoon Changhwan , Cho Soo-Jeong , Aksoy Bülent Arman , Park Do Joong , Schultz Nikolaus , Ryeom Sandra W. , Yoon Sam S.
Published: April 2023

Expression of self-renewal proteins, CD44, and RhoA in monolayer and spheroid cells.
Supplementary Data - Clean from Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials
Authors: Santiago-Walker Ademi , Gagnon Robert , Mazumdar Jolly , Casey Michelle , Long Georgina V. , Schadendorf Dirk , Flaherty Keith , Kefford Richard , Hauschild Axel , Hwu Patrick , Haney Patricia , O'Hagan Anne , Carver Jennifer , Goodman Vicki , Legos Jeffrey , Martin Anne-Marie
Published: April 2023

Supplementary Figure S1. Distribution of BRAF V600E cfDNA mutation fraction across study samples; Supplementary Figure S2. cfDNA-ND patients exhibited higher response rates to dabrafenib and trametinib compared with cfDNA V600E/K patients; Supplementary Table S1. Baseline clinical characteristics; Supplementary Table S2. Correlation between cfDNA mutation fraction, baseline tumor burden (SLD), and LDH; Supplementary Table S3. Association between cfDNA mutation fraction, with baseline covariates; Supplementary Table S4. Association between cfDNA mutation status, with baseline covariates; Supplementary Table S5. cfDNA-ND patients exhibited higher response rates to dabrafenib and trametinib compared with cfDNA V600E/K patients; Supplementary Table S6. cfDNA mutation fraction independently predicts PFS and OS in patients with baseline tumor V600E mutations
Supplemental Figure 1 from TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer
Authors: Forero-Torres Andres , Varley Katherine E. , Abramson Vandana G. , Li Yufeng , Vaklavas Christos , Lin Nancy U. , Liu Minetta C. , Rugo Hope S. , Nanda Rita , Storniolo Anna M. , Traina Tiffany A. , Patil Sujata , Van Poznak Catherine H. , Nangia Julie R. , Irvin William J. , Krontiras Helen , De Los Santos Jennifer F. , Haluska Paul , Grizzle William , Myers Richard M. , Wolff Antonio C.
Published: April 2023

1. Supplemental Data: Differential of Toxicity and Eligibility Critique.; 2. Supplemental Figure 1: Gene Expression in Patients With Response to Therapy.
Supplementary Tables 1-3, Supplementary Figures 1-7 from Mevalonate Pathway Antagonist Suppresses Formation of Serous Tubal Intraepithelial Carcinoma and Ovarian Carcinoma in Mouse Models
Authors: Kobayashi Yusuke , Kashima Hiroyasu , Wu Ren-Chin , Jung Jin-Gyoung , Kuan Jen-Chun , Gu Jinghua , Xuan Jianhua , Sokoll Lori , Visvanathan Kala , Shih Ie-Ming , Wang Tian-Li
Published: April 2023

Supplementary Tables 1-3, Supplementary Figures 1-7. Supplementary Table 1: Oligonucleotide primers used for qRT-PCR analysis. Supplementary Table 2: GSEA enrichment of KEGG functional pathways in lovastatin-regulated genes. Supplementary Table 3: Lovastatin affects expression of genes in glycolysis/gluconeogenesis pathway. Supplementary Figure 1: Daily administration of lovastatin prevents tumor growth in mogp-TAg transgenic mice. Supplementary Figure 2: Body weight and serum levels of cholesterol and triglyceride in mogp-TAg, SKOV3-IP, and OVCAR5 mouse tumor models. Supplementary Figure 3: Atorvastatin treatment delays growth of ovarian tumor xenografts. Supplementary Figure 4: Statin treatment increases transcript levels of LC3A and LC3B. Supplementary Figure 5: Scheme of the mevalonate pathway. Supplementary Figure 6: Applying GGPP or FPP as a single agent does not affect ovarian cancer cell proliferation. Supplementary Figure 7: Real-time qRT-PCR confirms knockdown efficiency of each siRNA.
Supplemental Figure 2 from A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma
Authors: Galloway Thomas J. , Wirth Lori J. , Colevas Alexander D. , Gilbert Jill , Bauman Julie E. , Saba Nabil F. , Raben David , Mehra Ranee , Ma Anna W. , Atoyan Ruzanna , Wang Jing , Burtness Barbara , Jimeno Antonio
Published: April 2023

Supplemental Figure 2. FISH analysis of EGFR and HER2 gene amplification in the archival tumor biopsies from 2 patients who received 275 mg/m2 of CUDC-101.
Supplementary Table 3 from Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets
Authors: Rekhtman Natasha , Pietanza Maria C. , Hellmann Matthew D. , Naidoo Jarushka , Arora Arshi , Won Helen , Halpenny Darragh F. , Wang Hangjun , Tian Shaozhou K. , Litvak Anya M. , Paik Paul K. , Drilon Alexander E. , Socci Nicholas , Poirier John T. , Shen Ronglai , Berger Michael F. , Moreira Andre L. , Travis William D. , Rudin Charles M. , Ladanyi Marc
Published: April 2023

Supplementary Table 3: Clinicopathologic characteristics
Supplementary Table 1 from Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets
Authors: Rekhtman Natasha , Pietanza Maria C. , Hellmann Matthew D. , Naidoo Jarushka , Arora Arshi , Won Helen , Halpenny Darragh F. , Wang Hangjun , Tian Shaozhou K. , Litvak Anya M. , Paik Paul K. , Drilon Alexander E. , Socci Nicholas , Poirier John T. , Shen Ronglai , Berger Michael F. , Moreira Andre L. , Travis William D. , Rudin Charles M. , Ladanyi Marc
Published: April 2023

Supplementary Table 1: Next-generation sequencing (MSK-IMPACT) gene panel
Supplemental Table 4 from KIT Exon 11 Codons 557–558 Deletion Mutation Promotes Liver Metastasis Through the CXCL12/CXCR4 Axis in Gastrointestinal Stromal Tumors
Authors: Wang Hao-Chen , Li Tzu-Ying , Chao Ying-Jui , Hou Ya-Chin , Hsueh Yuan-Shuo , Hsu Kai-Hsi , Shan Yan-Shen
Published: April 2023

Primers used for ChIP experiments
Supplementary Figures 1 to 6 from Head and Neck Squamous Cell Carcinomas Are Characterized by a Stable Immune Signature Within the Primary Tumor Over Time and Space
Authors: Wood Oliver , Clarke James , Woo Jeongmin , Mirza Adal H. , Woelk Christopher H. , Thomas Gareth J. , Vijayanand Pandurangan , King Emma , Ottensmeier Christian H.
Published: April 2023

Supplementary 1. Hierarchical clustering and Principle component analysis of all cases and all sequenced genes (n=18979). Supplementary Figure 2. Comparison of minimum and maximum Euclidean distance from hierarchical clustering of tumor replicates. Supplementary Figure 3. Spearman correlation analysis of all genes and all tumor replicates. Supplementary Figure 4. Gene expression profiles of immune genes across the sample cohort. Supplementary Figure 5. Hierarchical clustering of immune gene markers across the tumor replicates. Supplementary Figure 6. Spearman correlation analysis of CD8A gene expression and CD8 immunohistochemistry (IHC).
Supplementary legends from KRAS Mutation and Consensus Molecular Subtypes 2 and 3 Are Independently Associated with Reduced Immune Infiltration and Reactivity in Colorectal Cancer
Authors: Lal Neeraj , White Brian S. , Goussous Ghaleb , Pickles Oliver , Mason Mike J. , Beggs Andrew D. , Taniere Philippe , Willcox Benjamin E. , Guinney Justin , Middleton Gary W.
Published: April 2023

Supplementary figure legends
Supplemental Table 1 from Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients
Authors: Brand Toni M. , Hartmann Stefan , Bhola Neil E. , Peyser Noah D. , Li Hua , Zeng Yan , Isaacson Wechsler Erin , Ranall Max V. , Bandyopadhyay Sourav , Duvvuri Umamaheswar , LaVallee Theresa M. , Jordan Richard C.K. , Johnson Daniel E. , Grandis Jennifer R.
Published: April 2023

Clinical information describing pharyngeal cancer patient cohort
Figure S7 from KRAS Mutation and Consensus Molecular Subtypes 2 and 3 Are Independently Associated with Reduced Immune Infiltration and Reactivity in Colorectal Cancer
Authors: Lal Neeraj , White Brian S. , Goussous Ghaleb , Pickles Oliver , Mason Mike J. , Beggs Andrew D. , Taniere Philippe , Willcox Benjamin E. , Guinney Justin , Middleton Gary W.
Published: April 2023

CIRC expression is downregulated in CMS2 CRC.
Supplemental Figure 3 from Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients
Authors: Brand Toni M. , Hartmann Stefan , Bhola Neil E. , Peyser Noah D. , Li Hua , Zeng Yan , Isaacson Wechsler Erin , Ranall Max V. , Bandyopadhyay Sourav , Duvvuri Umamaheswar , LaVallee Theresa M. , Jordan Richard C.K. , Johnson Daniel E. , Grandis Jennifer R.
Published: April 2023

HPV(+) cell lines are sensitive to HER3 knockdown with a second independent siRNA
Figure S7 from Targeted Dual-Modality Imaging in Renal Cell Carcinoma: An Ex Vivo Kidney Perfusion Study
Authors: Hekman Marlène C.H. , Boerman Otto C. , de Weijert Mirjam , Bos Desirée L. , Oosterwijk Egbert , Langenhuijsen Hans F. , Mulders Peter F.A. , Rijpkema Mark
Published: April 2023

Biodistribution of Iodine-131-girentuximab-IRDye800CW and the irrelevant control Iodine-125-IgG-IRDye800CW in tumor and normal tissue samples. Left: first control experiment (#6). The mean tumor-to-normal-ratio for girentuximab and the irrelevant control antibody were 6 and 1, respectively. Right: second control experiment (#7). The mean tumor-to-normal-ratio for girentuximab and the irrelevant control antibody were 10 and 1, respectively.
Figure S6 from Targeted Dual-Modality Imaging in Renal Cell Carcinoma: An Ex Vivo Kidney Perfusion Study
Authors: Hekman Marlène C.H. , Boerman Otto C. , de Weijert Mirjam , Bos Desirée L. , Oosterwijk Egbert , Langenhuijsen Hans F. , Mulders Peter F.A. , Rijpkema Mark
Published: April 2023

Photograph (A) and autoradiographic image (B) of the second control experiment showing high uptake of Iodine-131-girentuximab-IRDye800CW in tumor tissue. The low energy gamma radiation of Iodine-125 is not visible in this autoradiography.
Figure S4 from Targeted Dual-Modality Imaging in Renal Cell Carcinoma: An Ex Vivo Kidney Perfusion Study
Authors: Hekman Marlène C.H. , Boerman Otto C. , de Weijert Mirjam , Bos Desirée L. , Oosterwijk Egbert , Langenhuijsen Hans F. , Mulders Peter F.A. , Rijpkema Mark
Published: April 2023

Tissue section of normal kidney parenchyma showing the absence of CAIX-expression (A) and corresponding absence of a radioactive (B) and fluorescent (C) signal in normal tissue. In the H&E staining detail (D) normal glomeruli are present lacking CAIX-expression (E) as seen in tumor tissue.
Supplementary Table S7 from Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer
Authors: Gyanchandani Rekha , Lin Yan , Lin Hui-Min , Cooper Kristine , Normolle Daniel P. , Brufsky Adam , Fastuca Michael , Crosson Whitney , Oesterreich Steffi , Davidson Nancy E. , Bhargava Rohit , Dabbs David J. , Lee Adrian V.
Published: April 2023

Differential risk stratification based on tumor sampling